在围产期药物流行病学中基因信息化研究设计:方法论概述
Alexis C Carson1,2, Mahmoud Zidan1,2,3, Emilie Willoch Olstad1,2
1PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.
Drug safety
|March 2, 2026
概括
有基因信息的研究设计可以提高怀孕期间药物的安全性评估. 这些方法解决了观察性研究中的偏差,加强了围产期药物流行病学中儿童结果的因果推断.
科学领域:
- 周产期药学流行病学
- 遗传流行病学遗传流行病学
- 因果推理因果推理
背景情况:
- 在怀孕期间临床试验药物安全性在道德和方法上具有挑战性.
- 观察性研究至关重要,但由于缺乏随机化,容易产生偏见.
- 整合遗传信息有可能减轻围产期药物流行病学中的混.
研究的目的:
- 对围产期药物流行病学中儿童结果的基因知情研究设计进行审查.
- 讨论这些方法的优点,局限性和当前应用.
- 概述研究中未来实施的考虑因素.
主要方法:
- 对基因信息设计的审查:不和的兄弟设计,多基因分数和门德尔随机化.
- 对它们在围产期药物流行病学中的应用进行分析,以了解儿童的结局.
- 讨论包括数据可用性和整合在内的挑战.
主要成果:
- 基因知情设计可以解决混问题,并加强观察性研究中的因果推断.
- 这些方法在围产期药物流行病学中的应用仍然有限但有前途.
- 成功实施需要仔细考虑遗传数据的整合和仪器的选择.
结论:
- 基因知情的研究设计提供了一种强有力的方法,以加强围产期药理学流行病学中的因果推断.
- 通过遗传数据解决偏见可以改善怀孕期间对药物安全性的评估.
- 未来的研究应该专注于克服实施障碍,以利用这些先进的方法.
相关概念视频
Analysis of Population Pharmacokinetic Data
872
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
872
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
508
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
508
Pharmacogenetics and Pharmacogenomics: Overview
83
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
83
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
65
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65
Pharmacokinetics in Pediatric Patients: Drug Distribution
388
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
388
Pharmacokinetics in Pediatric Patients: Drug Metabolism
293
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293


